A research team have recently published their article, "Rationally designed pooled CRISPRi-seq uncovers an inhibitor of ...

We recently published a list of 10 Worst ARK Stocks To Buy According to Short Sellers. In this article, we are going to take ...

Research analysts at William Blair issued their FY2024 earnings per share estimates for shares of CRISPR Therapeutics in a report issued on Monday, December 9th. William Blair analyst S. Corwin ...

How does CRISPR work, and why is editing human embryos so controversial? Explore the science, the risks, and the ethical debates surrounding Dr. He Jiankui’s gene-editing experiment.

When hiring job candidates to work on cell and gene therapies, companies look for more than just technical skills. Talent ...

I am glad that these negative results are finally shared, as it helps prevent duplication of work and unnecessary suffering in laboratory animals.” ...

The merger of Nvelop Therapeutics and Chroma Medicine brings together a combination of epigenetic editing and in vivo ...

November 2024 has seen a variety of biotech deals take place to advance therapies across different stages in development.

With a new CEO at the helm, Swiss CDMO Lonza is looking to revivify its business by doubling down on contract manufacturing ...

The new company has also raised $75 million that will support the development of epigenetic editing therapies for hepatitis B ...

Fintel reports that on December 11, 2024, Wells Fargo downgraded their outlook for Editas Medicine (NasdaqGS:EDIT) from ...

Depth Assessment of the Synthetic Biology Industry by Tools, Technologies, Applications, and Regions, Featuring Profiles of ...